Search Results

You are looking at 1 - 10 of 29 items for :

  • "Cushing’s disease" x
Clear All
Open access

Alberto Giacinto Ambrogio, Massimiliano Andrioli, Martina De Martin, Francesco Cavagnini and Francesca Pecori Giraldi

Introduction First-line treatment of Cushing’s disease is surgical removal of the ACTH-secreting pituitary tumor and worldwide remission rates range from 60 to 80% ( 1 , 2 , 3 ). The tumor may recur, however, most often within two years of

Open access

Prachi Bansal, Anurag Lila, Manjunath Goroshi, Swati Jadhav, Nilesh Lomte, Kunal Thakkar, Atul Goel, Abhidha Shah, Shilpa Sankhe, Naina Goel, Neelam Jaguste, Tushar Bandgar and Nalini Shah

Introduction Cushing’s disease (CD) is a state of cortisol excess, caused by an ACTH-secreting pituitary adenoma. Although a rare disease with an annual incidence of 1.5 patients/million ( 1 ), it is associated with significant morbidity and

Open access

Emmanuelle Motte, Anya Rothenbuhler, Stephan Gaillard, Najiba Lahlou, Cécile Teinturier, Régis Coutant and Agnès Linglart

Introduction Cushing’s disease (CD) is characterized by adrenocorticotropin (ACTH)-dependent cortisol excess originating from a pituitary adenoma and accounts for approximately 85% of cases of pediatric Cushing’s syndrome ( 1 , 2 , 3 , 4

Open access

Nidan Qiao

Introduction Cushing’s disease (CD) is a subtype of pituitary adenoma with hypercortisolism and presents a particular challenge to neurosurgeons. Transsphenoidal surgery (TS) has long been the standard of care for patients with CD ( 1 , 2

Open access

Lang Qin, Xiaoming Zhu, Xiaoxia Liu, Meifang Zeng, Ran Tao, Yan Zhuang, Yiting Zhou, Zhaoyun Zhang, Yehong Yang, Yiming Li, Yongfei Wang and Hongying Ye

Introduction Hypertension is a common chronic condition in patients with Cushing’s disease (CD) and may be the first sign ( 1 ). The pathogenesis of glucocorticoid-induced hypertension is not fully understood. It is thought to be related in

Open access

Boni Xiang, Ran Tao, Xinhua Liu, Xiaoming Zhu, Min He, Zengyi Ma, Yehong Yang, Zhaoyun Zhang, Yiming Li, Zhenwei Yao, Yongfei Wang and Hongying Ye

(ACTH)-dependent ( 1 ), and 20% is ACTH-independent. Pituitary corticotroph adenoma (Cushing’s disease (CD)) is the most common cause ( 2 ), followed by primary unilateral adrenal adenomas and ectopic adrenocorticotropic syndrome (EAS). The clinical

Open access

Anastasia P Athanasoulia-Kaspar, Matthias K Auer, Günter K Stalla and Mira Jakovcevski

premature aging by inducing accelerated telomere shortening, which might be an explanation for persistent high morbidity and other clinical consequences associated with Cushing’s disease, even years after successful treatment for hypercortisolism. This

Open access

Kush Dev Singh Jarial, Anil Bhansali, Vivek Gupta, Paramjeet Singh, Kanchan K Mukherjee, Akhilesh Sharma, Rakesh K Vashishtha, Suja P Sukumar, Naresh Sachdeva and Rama Walia

% diagnostic accuracy ( 1 ). Cushing’s disease (CD) accounts for about 90–95% of the cases when there is no obvious source of ACTH hypersecretion, and this distinction is essential to decide further therapeutic strategies ( 2 , 3 , 4 , 5 ). Sellar imaging

Open access

Nidan Qiao

pituitary neoplasms, acromegaly, Cushing’s disease, craniopharyngioma and growth hormone deficiency. More than half of the studies were published in the recent 2 years. Table 2 Summary of studies on sellar region disease using machine learning methods

Open access

Boni Xiang, Ran Tao, Xinhua Liu, Xiaoming Zhu, Min He, Zengyi Ma, Yehong Yang, Zhaoyun Zhang, Yiming Li, Zhenwei Yao, Yongfei Wang and Hongying Ye

Objective: The aim of this study was to evaluate thyroid function in Cushing’s syndrome (CS), and the dynamic changes of thyroid hormones and antithyroid antibodies in Cushing’s disease (CD) pre- and postoperatively.

Design and Methods: This is a retrospective study enrolling 118 patients with CS [102 CD, 10 adrenal CS and 6 ectopic adrenocorticotropic syndrome (EAS)]. Thyroid functions [thyroid-stimulation hormone (TSH), T3, free T3 (FT3), T4, and free T4 (FT4)] were measured in all CS at the time of diagnosis and in all CD 3 months after transsphenoidal pituitary tumor resection. Postoperative hormone monitoring within 3 months was conducted in 9 CD patients completing remission. 28 remitted CD patients experienced hormone and antithyroid antibody evaluation preoperatively and on the 3rd, 6th, and 12th month after surgery.

Results: TSH, T3, and FT3 were below the reference range in 31%, 69% and 44% of the 118 CS patients. Remitted CD patients (81/102) had significantly higher TSH (P=0.000), T3 (P=0.000), and FT3 (P=0.000) than those in the non-remission group (21/102). After remission of CD, TSH, T3, and FT3 showed a significant increase, with a few cases above the reference range. By 12 months, most CD patients’ thyroid functions returned to normal. Thyroid hormones (including TSH, T3, and FT3) were negatively associated with serum cortisol levels both before and after surgery. No significant changes of antithyroid autoantibodies were observed.

Conclusions: TSH, T3, and FT3 are suppressed in endogenous hypercortisolemia. After remission of CD, TSH, T3, and FT3 increased significantly, even above the reference range, but returned to normal one year after surgery in most cases. Antithyroid antibodies didn’t change significantly after remission of CD.